BTK inhibitor CC-292
An orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity. By irreversibly inhibiting BTK, administration of this agent may lead to an inhibition of B cell receptor (BCR) signaling and may inhibit cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
Synonym: | Bruton's tyrosine kinase inhibitor AVL-292 Bruton's tyrosine kinase inhibitor CC-292 BTK inhibitor AVL-292 |
---|---|
Code name: | AVL-292 CC-292 |